Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6468559B1 · kind B1 · utility
106Cited by
12References
59Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 28, 2000 |
| Grant date | Oct 22, 2002 |
| Priority date | — |
| Expiry date | Apr 28, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/4858
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Oral dosage forms are provided for the administration of a bisphosphonic acid compound in the prevention and treatment of conditions involving calcium or phosphate metabolism, i.e., conditions associated with bone resorption such as osteoporosis, Paget's disease, periprosthetic bone loss, osteolysis, malignant hypercalcemia, metastatic bone disease, multiple myeloma, and periodontal disease. The dosage forms are either enterically coated capsules housing the drug in a liquid or semi-solid carrier, or enterically coated osmotically activated drug delivery devices.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.